Physician
The Children's Hospital of Alabama
The Children's Hospital of Alabama was paid $17.71M by Medicaid between Jan 2018 and Dec 2024, across 78 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 31% of everything it billed.
33Billing provider infoTHE CHILDREN'S HOSPITAL OF ALABAMA
HOOVER, AL 35244
HOOVER, AL 35244
33aNPI1124105762assigned 11/01/2006
33bProvider typePediatrics Physician
28Total paid$17.71M
24GClaims382,108
24DCodes billed78
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Alabama
Rank by total paid#10 of 199
Median peer was paid$702K
This provider vs. median25×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WALTON, DAWN controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43,903 | $2.38M | |
| 2019 | 53,163 | $2.29M | |
| 2020 | 43,476 | $1.89M | |
| 2021 | 64,776 | $2.87M | |
| 2022 | 65,036 | $2.88M | |
| 2023 | 58,274 | $2.66M | |
| 2024incomplete | 53,480 | $2.74M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 31% | 80,562 | 74,212 | $5.46M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 19% | 34,084 | 31,839 | $3.32M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 6.8% | 15,621 | 15,356 | $1.20M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 5.2% | 12,244 | 12,071 | $930K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.5% | 10,305 | 10,120 | $796K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.3% | 18,301 | 17,562 | $755K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.4% | 13,449 | 12,975 | $610K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 3.3% | 7,912 | 7,817 | $576K |
| 90670 | 2.8% | 8,873 | 8,721 | $489K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.2% | 4,524 | 4,445 | $387K |
| 90698 | 1.7% | 9,574 | 9,440 | $305K | |
| 90461 | 1.5% | 4,399 | 4,365 | $271K |
66 more codes
| 90680 | 1.4% | 6,530 | $243K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.3% | 18,496 | $223K |
| 90651 | 1.2% | 1,599 | $220K | |
| 90686 | 1.2% | 11,365 | $216K | |
| 90710 | <1% | 1,764 | $141K | |
| 87070 | <1% | 14,246 | $134K | |
| 90677 | <1% | 1,681 | $121K | |
| 90716 | <1% | 1,488 | $107K | |
| 90633 | <1% | 3,758 | $90K | |
| 90671 | <1% | 1,139 | $78K | |
| 90744 | <1% | 3,609 | $76K | |
| 99173 | <1% | 19,424 | $75K | |
| 90734 | <1% | 870 | $74K | |
| 92551 | <1% | 16,594 | $71K | |
| 90707 | <1% | 1,421 | $69K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,181 | $65K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,331 | $64K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,531 | $46K |
| 96127 | <1% | 6,731 | $40K | |
| 90619 | <1% | 436 | $39K | |
| 90700 | <1% | 1,654 | $38K | |
| 90713 | <1% | 1,156 | $36K | |
| 87634 | <1% | 802 | $36K | |
| 90685 | <1% | 1,647 | $32K | |
| 99051 | <1% | 1,564 | $31K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,642 | $30K |
| 80061 | Lipid panel | <1% | 1,859 | $23K |
| 90656 | <1% | 1,130 | $22K | |
| 99177 | <1% | 936 | $19K | |
| 90715 | <1% | 604 | $17K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 151 | $17K |
| 36416 | <1% | 14,082 | $14K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 129 | $10K |
| 90696 | <1% | 262 | $10K | |
| 90648 | <1% | 929 | $10K | |
| 83655 | <1% | 665 | $9K | |
| 0072A | <1% | 200 | $8K | |
| 99381 | <1% | 96 | $6K | |
| 0001A | <1% | 182 | $6K | |
| 0071A | <1% | 185 | $6K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 226 | $5K |
| 0002A | <1% | 147 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,424 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 147 | $3K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 31 | $3K |
| 90672 | <1% | 138 | $3K | |
| 99461 | <1% | 28 | $2K | |
| 81003 | <1% | 865 | $2K | |
| 99383 | <1% | 27 | $1K | |
| 69210 | <1% | 41 | $1K | |
| 99000 | <1% | 916 | $949.67 | |
| 90660 | <1% | 29 | $725.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 70 | $616.42 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 37 | $573.78 |
| 0081A | <1% | 13 | $480.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 351 | $447.42 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 57 | $438.36 |
| 94760 | <1% | 1,199 | $433.94 | |
| 96380 | <1% | 17 | $416.56 | |
| 99401 | <1% | 16 | $307.08 | |
| 96161 | <1% | 72 | $227.47 | |
| 85013 | <1% | 60 | $160.46 | |
| 92558 | <1% | 13 | $142.68 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 13 | $4.94 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 271 | $0.00 |
| 99080 | 0% | 1,983 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALTON, DAWN (CFO)
Parent organizationTHE CHILDREN'S HOSPITAL OF ALABAMA
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.